CDC and FDA are working together to coordinate analysis of vaping products, including e-cigarettes, to provide insight into the nature of the chemical exposure(s) contributing to the Lung Injury outbreak. FDA is analyzing e-liquids for the presence of a broad range of chemicals. When sufficient liquid product is available, CDC will conduct aerosol emissions testing of the e-cigarette or other vaping product. The graphic below outlines the process for states to submit product samples to FDA and CDC for testing.
Analysis of both e-liquid and aerosol emissions will complement each other, and together will help improve our understanding of exposure among case patients associated with the Lung Injury outbreak.
States can request to submit product to either CDC or FDA. Product(s) must be linked to a confirmed or probable case and have a CDC case ID.
For information about collection and submission of e-cigarette or other vaping products, including e-liquids, associated with confirmed or probable cases for possible testing by FDA, contact: FDAVapingSampleInquiries@fda.hhs.gov.
For information about collection and submission of e-cigarette or other vaping products’ e-liquids associated with confirmed or probable cases for possible aerosol emissions testing by CDC, contact IncidentResponse@cdc.gov.